Page 2,430«..1020..2,4292,4302,4312,432..2,4402,450..»

New reporter system to study bone-related regenerative medicine generated by UMN labs

Posted: Published on March 11th, 2015

MINNEAPOLIS/ST. PAUL (2/10/2015) - A new reporter system used to study the bone regeneration potential of human embryonic stem cells has been generated in research led by the University of Minnesota. The new reporter system is the first of its kind for human pluripotent stem cells and is important for identifying certain agents and pathways that mediate early stages of human bone development. The research is published today in the journal Stem Cell Reports. The RUNX2-yellow fluorescent protein reporter system allows researchers to learn whether a human pluripotent stem cell-derived cell tests positive (or negative) for certain properties. Cells testing positive have been shown previously to repair bone in the skulls of immunodeficient mice. An improved understanding of whether a cell tests positive or negative through the RUNX2-yellow fluorescent protein reporter system will allow researchers to better monitor which types of cells produced from human pluripotent stem cells might be best suited to regenerating bone. The Stem Cell Reports publication comes on the heels of a complementary finding led by the same group of University of Minnesota researchers published in December in the journal Stem Cells. The Stem Cells publication specified a new reporter system to identify and isolate a … Continue reading →

Posted in Stem Cell Research | Comments Off on New reporter system to study bone-related regenerative medicine generated by UMN labs

Researchers from Stanford University and 23andMe discover genetic links to rosacea

Posted: Published on March 11th, 2015

First ever genome-wide association study on common, incurable skin condition pinpoints 2 genetic variants associated with rosacea MOUNTAIN VIEW, Calif., March 10, 2015 -- Today marked the publication of the first ever genome-wide association study of rosacea, a common and incurable skin disorder. Led by Dr. Anne Lynn S. Chang of Stanford University's School of Medicine, and co-authored by 23andMe, the study is the first to identify genetic factors for this condition. Rosacea (pronounced roh-ZAY-sha) is estimated to affect more than 16 million people in the United States alone1. Symptoms typically include redness, visible blood vessels, and pimple-like sores on the skin of the central face, and many experience stinging, burning, or increased sensitivity over the affected skin. Because rosacea affects facial appearance, it can also have a psychological impact on those who suffer from it. In surveys by the National Rosacea Society, more than 76 percent of rosacea patients said their condition had lowered their self-confidence and self-esteem. To help better understand the genetics of rosacea, researchers at Stanford University and 23andMe studied the data of more than 46,000 23andMe customers* consented for research. The study, published in the Journal of Investigative Dermatology, found two genetic variants strongly associated … Continue reading →

Comments Off on Researchers from Stanford University and 23andMe discover genetic links to rosacea

Stem Cell Transplant/ Bone Marrow Transplant – Video

Posted: Published on March 10th, 2015

Stem Cell Transplant/ Bone Marrow Transplant By: 7721480 … Continue reading →

Posted in Stem Cell Transplant | Comments Off on Stem Cell Transplant/ Bone Marrow Transplant – Video

Johns Hopkins Researchers Engineer Custom Blood Cells

Posted: Published on March 10th, 2015

Contact Information Available for logged-in reporters only Newswise Researchers at Johns Hopkins have successfully corrected a genetic error in stem cells from patients with sickle cell disease, and then used those cells to grow mature red blood cells, they report. The study represents an important step toward more effectively treating certain patients with sickle cell disease who need frequent blood transfusions and currently have few options. The results appear in an upcoming issue of the journal Stem Cells. In sickle cell disease, a genetic variant causes patients blood cells to take on a crescent, or sickle, shape, rather than the typical round shape. The crescent-shaped cells are sticky and can block blood flow through vessels, often causing great pain and fatigue. Getting a transplant of blood-making bone marrow can potentially cure the disease. But for patients who either cannot tolerate the transplant procedure, or whose transplants fail, the best option may be to receive regular blood transfusions from healthy donors with matched blood types. The problem, says Linzhao Cheng, Ph.D., the Edythe Harris Lucas and Clara Lucas Lynn Professor of Hematology and a member of the Institute for Cell Engineering, is that over time, patients bodies often begin to mount … Continue reading →

Posted in Stem Cell Transplant | Comments Off on Johns Hopkins Researchers Engineer Custom Blood Cells

Building custom blood cells to battle sickle cell disease

Posted: Published on March 10th, 2015

March 10, 2015 These are human blood cells grown in the lab from genetically edited stem cells. (Credit: Ying Wang/Johns Hopkins Medicine) Provided by Shawna Williams, Johns Hopkins Medicine Researchers at Johns Hopkins have successfully corrected a genetic error in stem cells from patients with sickle cell disease, and then used those cells to grow mature red blood cells, they report. The study represents an important step toward more effectively treating certain patients with sickle cell disease who need frequent blood transfusions and currently have few options. The results appear in an upcoming issue of the journalStem Cells. In sickle cell disease, a genetic variant causes patients blood cells to take on a crescent, or sickle, shape, rather than the typical round shape. The crescent-shaped cells are sticky and can block blood flow through vessels, often causing great pain and fatigue. Getting a transplant of blood-making bone marrow can potentially cure the disease. But for patients who either cannot tolerate the transplant procedure, or whose transplants fail, the best option may be to receive regular blood transfusions from healthy donors with matched blood types. [STORY: New injection helps stem traumatic blood loss] The problem, says Linzhao Cheng, Ph.D. , the … Continue reading →

Posted in Stem Cell Transplant | Comments Off on Building custom blood cells to battle sickle cell disease

Evocure – Crowdfunding on MyMicroInvest fr/nl – Video

Posted: Published on March 10th, 2015

Evocure - Crowdfunding on MyMicroInvest fr/nl EVOCURE fits within the cosmeceutics trend, on the border of the pharmaceutical world and traditional cosmetics, following the principle of using exclusive... By: MyMicroInvest Crowdfunding … Continue reading →

Posted in Aesthetic Medicine | Comments Off on Evocure – Crowdfunding on MyMicroInvest fr/nl – Video

Stem Cell Treatments that work Nova Cells Institute, 562-916-3410 – Video

Posted: Published on March 10th, 2015

Stem Cell Treatments that work Nova Cells Institute, 562-916-3410 Stem Cell Treatments that work from Nova Cells Institute, NCIM makes a difference because we care - http:www.novacellsinstitute.com. By: NCIM … Continue reading →

Posted in Stem Cell Treatments | Comments Off on Stem Cell Treatments that work Nova Cells Institute, 562-916-3410 – Video

FDA Approves Unituxin (dinutuximab) for the Treatment of Pediatric High-Risk Neuroblastoma

Posted: Published on March 10th, 2015

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., March 10, 2015 /PRNewswire/ --United Therapeutics Corporation (NASDAQ: UTHR) announced today that the United States Food and Drug Administration (FDA) has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.Neuroblastoma is the most common extracranial solid cancer in childhood and the most common cancer in infancy, with an annual incidence in the United States of approximately 700 patients, of whom 50% are diagnosed as having high-risk disease. Unituxin is a chimeric biologic antibody that induces cell lysis of GD2-expressing cells through antibody-dependent cell-mediated cytoxicity (ADCC) and complement-dependent cytoxicity (CDC) and is part of an immunotherapeutic regimen to treat pediatric high-risk neuroblastoma. The approval was based on demonstration of improved event-free survival (EFS) and overall survival (OS) in a multicenter, open-label, randomized trial (ANBL0032) conducted by the Children's Oncology Group (COG). The trial randomized (1:1) 226 patients to either the Unituxin/13-cis-retinoic acid (RA) arm or the RA alone arm. Patients in each arm received six cycles of treatment. The Unituxin/RA … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on FDA Approves Unituxin (dinutuximab) for the Treatment of Pediatric High-Risk Neuroblastoma

Dementia Stem Cell Treatment review, Nova Cells Institute, 562-916-3410 – Video

Posted: Published on March 10th, 2015

Dementia Stem Cell Treatment review, Nova Cells Institute, 562-916-3410 Dementia Stem Cell Treatment review from Nova Cells Institute, NCIM is making a difference because we care - 562-916-3410 - http://www.novacellsinstitute.com... By: NCIM … Continue reading →

Comments Off on Dementia Stem Cell Treatment review, Nova Cells Institute, 562-916-3410 – Video

Targazyme Inc. Receives Orphan Drug Designation to TZ101 for Use With Regulatory T Cells to Prevent & Reduce the …

Posted: Published on March 10th, 2015

Orphan Designation Provides 7-Year Post Approval Marketing Exclusivity, Tax Credits and Elimination of FDA Prescription Drug User Fees SAN DIEGO, CA--(Marketwired - February 10, 2015) - Targazyme Inc., a clinical-stage biopharmaceutical company developing enzyme technologies and products to improve efficacy outcomes for stem cell transplantation, immunotherapy, gene therapy and regenerative medicine, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to TZ101 to prevent and reduce the severity and incidence of graft vs. host disease (GVHD) in patients eligible for hematologic stem cell transplant. GVHD is a serious, life-threating complication of stem cell transplantation.Orphan drug status confirms the importance of Targazyme's novel treatment approach to prevent and reduce the incidence and severity of GVHD in patients with blood cancers where stem cell transplant is prescribed.TZ101 could potentially transform hematopoietic stem cell transplantation by reducing patient morbidity and mortality from GVHD, which occurs in a large percentage of these patients and is very difficult to manage clinically. "Our work with TZ101 demonstrates impressive increases in the persistence and activity of regulatory T cells in preclinical models of GVHD," said Dr. Elizabeth J. Shpall, Deputy Chair of the Department of Stem Cell Transplantation and Cellular Therapy … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Targazyme Inc. Receives Orphan Drug Designation to TZ101 for Use With Regulatory T Cells to Prevent & Reduce the …

Page 2,430«..1020..2,4292,4302,4312,432..2,4402,450..»